Columbia Trust Co 01012016 Acquires 142 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Columbia Trust Co 01012016 raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,265 shares of the biopharmaceutical company’s stock after buying an additional 142 shares during the quarter. Columbia Trust Co 01012016’s holdings in Regeneron Pharmaceuticals were worth $1,111,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Sunbelt Securities Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $25,000. Fortitude Family Office LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Bruce G. Allen Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $40,000. Finally, Sutton Wealth Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research reports. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a report on Tuesday, February 6th. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Barclays boosted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $967.59.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $2.46 during mid-day trading on Tuesday, reaching $963.55. 386,832 shares of the stock traded hands, compared to its average volume of 505,962. The stock has a market capitalization of $105.76 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 2.78 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The business’s 50-day moving average is $957.02 and its 200-day moving average is $877.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $10.96 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 18,226 shares of company stock worth $17,061,869 over the last quarter. 8.83% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.